Ebola virus antibody decay–stimulation in a high proportion of survivors
- 27 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 590 (7846), 468-472
- https://doi.org/10.1038/s41586-020-03146-y
Abstract
Neutralizing antibody function provides a foundation for the efficacy of vaccines and therapies1,2,3. Here, using a robust in vitro Ebola virus (EBOV) pseudo-particle infection assay and a well-defined set of solid-phase assays, we describe a wide spectrum of antibody responses in a cohort of healthy survivors of the Sierra Leone EBOV outbreak of 2013–2016. Pseudo-particle virus-neutralizing antibodies correlated with total anti-EBOV reactivity and neutralizing antibodies against live EBOV. Variant EBOV glycoproteins (1995 and 2014 strains) were similarly neutralized. During longitudinal follow-up, antibody responses fluctuated in a ‘decay–stimulation–decay’ pattern that suggests de novo restimulation by EBOV antigens after recovery. A pharmacodynamic model of antibody reactivity identified a decay half-life of 77–100 days and a doubling time of 46–86 days in a high proportion of survivors. The highest antibody reactivity was observed around 200 days after an individual had recovered. The model suggests that EBOV antibody reactivity declines over 0.5–2 years after recovery. In a high proportion of healthy survivors, antibody responses undergo rapid restimulation. Vigilant follow-up of survivors and possible elective de novo antigenic stimulation by vaccine immunization should be considered in order to prevent EBOV viral recrudescence in recovering individuals and thereby to mitigate the potential risk of reseeding an outbreak.This publication has 59 references indexed in Scilit:
- Molecular Evolution of Viruses of the Family Filoviridae Based on 97 Whole-Genome SequencesJournal of Virology, 2013
- Accurate Detection of Outliers and Subpopulations With Pmetrics, a Nonparametric and Parametric Pharmacometric Modeling and Simulation Package for RTherapeutic Drug Monitoring, 2012
- The role of population PK–PD modelling in paediatric clinical researchEuropean Journal of Clinical Pharmacology, 2010
- Evidence that Ecotropic Murine Leukemia Virus Contamination in TZM-bl Cells Does Not Affect the Outcome of Neutralizing Antibody Assays with Human Immunodeficiency Virus Type 1Journal of Virology, 2009
- Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal ruleNature Reviews Microbiology, 2009
- Identification of Gammaretroviruses Constitutively Released from Cell Lines Used for Human Immunodeficiency Virus ResearchJournal of Virology, 2008
- Recent Common Ancestry of Ebola Zaire Virus Found in a Bat ReservoirPLoS Pathogens, 2006
- Antibody neutralization and escape by HIV-1Nature, 2003
- Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) MonotherapyAntimicrobial Agents and Chemotherapy, 2002
- Vpr Is Required for Efficient Replication of Human Immunodeficiency Virus Type-1 in Mononuclear PhagocytesVirology, 1995